Century Therapeutics: A Biotech With Interesting Optionality Opportunities
Source: SeekingAlpha
2026-04-24 07:22:01 ET
Investment Thesis
I value Century Therapeutics (NASDAQ: IPSC) with a speculative buy rating. The company has undergone a pivotal restructuring in its pipeline, deprioritizing oncology programs in favor of autoimmune CAR cells and the innovative CNTY-813, treating Type 1 diabetes....
Read the full article on Seeking Alpha
For further details see:
Century Therapeutics: A Biotech With Interesting Optionality Opportunities
Century Therapeutics Inc.
NASDAQ: IPSC
IPSC Trading
-7.15% G/L:
$2.015 Last:
882,555 Volume:
$2.17 Open:
IPSC Latest News
May 14, 2026 08:00:00 am
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
May 13, 2026 08:00:00 am
Century Therapeutics Reports First Quarter Financial Results and Business Updates
IPSC Stock Data
$358,397,419
106,369,480
5.86%
10
N/A
Biotechnology & Life Sciences
Healthcare
US
Philadelphia
